Company profile: DiscGenics
1.1 - Company Overview
Company description
- Provider of regenerative cell therapy for chronic back pain, offering IDCT (rebonuputemcel), an injectable therapy using proprietary Discogenic Cells to treat mild to moderate degenerative disc disease. Discogenic Cells are biomedically engineered progenitor cells derived from human intervertebral disc tissue, designed to address the environment of a degenerated disc.
Products and services
- IDCT (rebonuputemcel): An injectable cell therapy using proprietary Discogenic Cells to treat mild to moderate degenerative disc disease by addressing the environment of a degenerated disc
- Regenerative Cell Therapy for Chronic Back Pain: Delivers an injectable therapy using Discogenic Cells to address a degenerated disc’s environment and treat mild to moderate degenerative disc disease
- Discogenic Cells: Biomedically engineered progenitor cells derived from human intervertebral disc tissue, architected to address the environment of a degenerated disc for degenerative disc disease applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DiscGenics
Imel Biotherapeutics
HQ: United States
Website
- Description: Provider of cell-based therapies for mitochondrial disorders, including autologous mitochondria-replaced T cells (Mir T Cells) and mitochondrial enhancement therapies that replace dysfunctional mitochondria with healthy ones to restore cellular functionality, reprogram T cells, and overcome T cell exhaustion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imel Biotherapeutics company profile →
Sernova
HQ: Canada
Website
- Description: Provider of regenerative medicine therapeutic technologies, including the Cell Pouch System, an implantable device that creates a vascularized environment for the long-term survival and function of therapeutic cells; immune protection technologies (microencapsulation and systemic therapies); and therapeutic cells, with clinical programs for insulin-dependent diabetes, hemophilia A, and thyroid disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sernova company profile →
Advanced Cell Technology
HQ: United States
Website
- Description: Provider of stem cell-based regenerative therapies, including human embryonic stem cell-derived retinal pigment epithelial (RPE) therapy for retinal degenerative diseases such as Stargardt's disease and dry age-related macular degeneration; a hemangioblast (HG) platform for blood and cardiovascular diseases with CHA Biotech; and myoblast autologous adult stem cell therapy for heart failure, advanced cardiac disease, myocardial infarction, and ischemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Cell Technology company profile →
AgeX Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics for age-related degenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AgeX Therapeutics company profile →
Medistem
HQ: United States
Website
- Description: Provider of adult stem cell-based therapeutic products through development, acquisition, and commercialization. Founded in 2005, the company holds 16 families of patent applications, has numerous scientific publications, and generates revenue by out-licensing certain technologies. Main candidate: Endometrial Regenerative Cell (ERC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medistem company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DiscGenics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DiscGenics
2.2 - Growth funds investing in similar companies to DiscGenics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DiscGenics
4.2 - Public trading comparable groups for DiscGenics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →